# The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

> **NCT06295094** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Odense University Hospital** · enrollment: 264 (estimated)

## Conditions studied

- Gastric Cancer
- Chemotherapy, Adjuvant
- Peritoneal Metastases
- Minimally Invasive Surgical Procedures

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT06295094
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06295094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06295094, "The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06295094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*